Codexis, Inc. Common Stock

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 146 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.